These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
256 related articles for article (PubMed ID: 32070778)
1. Synthetic lethality: A promising therapeutic strategy for hepatocellular carcinoma. Tang L; Chen R; Xu X Cancer Lett; 2020 Apr; 476():120-128. PubMed ID: 32070778 [TBL] [Abstract][Full Text] [Related]
2. BRD4 inhibition induces synthetic lethality in ARID2-deficient hepatocellular carcinoma by increasing DNA damage. He DD; Shang XY; Wang N; Wang GX; He KY; Wang L; Han ZG Oncogene; 2022 Mar; 41(10):1397-1409. PubMed ID: 35017665 [TBL] [Abstract][Full Text] [Related]
3. Current discovery strategies for hepatocellular carcinoma therapeutics. Dai Q; Zhang C; Yuan Z; Sun Q; Jiang Y Expert Opin Drug Discov; 2020 Feb; 15(2):243-258. PubMed ID: 31809618 [No Abstract] [Full Text] [Related]
4. Integrating Genomics Into Clinical Practice in Hepatocellular Carcinoma: The Challenges Ahead. Pillai A; Ahn J; Kulik L Am J Gastroenterol; 2020 Dec; 115(12):1960-1969. PubMed ID: 33038134 [TBL] [Abstract][Full Text] [Related]
5. Targeting the TCA cycle through cuproptosis confers synthetic lethality on ARID1A-deficient hepatocellular carcinoma. Xing T; Li L; Chen Y; Ju G; Li G; Zhu X; Ren Y; Zhao J; Cheng Z; Li Y; Xu D; Liang J Cell Rep Med; 2023 Nov; 4(11):101264. PubMed ID: 37939712 [TBL] [Abstract][Full Text] [Related]
6. Genome-wide CRISPR screen identifies synthetic lethality between DOCK1 inhibition and metformin in liver cancer. Feng J; Lu H; Ma W; Tian W; Lu Z; Yang H; Cai Y; Cai P; Sun Y; Zhou Z; Feng J; Deng J; Shu Y; Qu K; Jia W; Gao P; Zhang H Protein Cell; 2022 Nov; 13(11):825-841. PubMed ID: 35217990 [TBL] [Abstract][Full Text] [Related]
7. Hepatocellular carcinoma-targeted drug discovery through image-based phenotypic screening in co-cultures of HCC cells with hepatocytes. Jang JW; Song Y; Kim KM; Kim JS; Choi EK; Kim J; Seo H BMC Cancer; 2016 Oct; 16(1):810. PubMed ID: 27756242 [TBL] [Abstract][Full Text] [Related]
8. Ter-cell, A New Target for Hepatocellular Carcinoma Therapy. Cen X; Cheng K Chembiochem; 2018 Nov; 19(21):2254-2256. PubMed ID: 30136761 [TBL] [Abstract][Full Text] [Related]
9. Pharmacologically inducing anoikis offers novel therapeutic opportunities in hepatocellular carcinoma. Wang Y; Fleishman JS; Wang J; Chen J; Zhao L; Ding M Biomed Pharmacother; 2024 Jul; 176():116878. PubMed ID: 38843588 [TBL] [Abstract][Full Text] [Related]
10. Multiple Roles of Autophagy in the Sorafenib Resistance of Hepatocellular Carcinoma. Sun T; Liu H; Ming L Cell Physiol Biochem; 2017; 44(2):716-727. PubMed ID: 29169150 [TBL] [Abstract][Full Text] [Related]
11. Non-coding RNA in drug resistance of hepatocellular carcinoma. Ding B; Lou W; Xu L; Fan W Biosci Rep; 2018 Oct; 38(5):. PubMed ID: 30224380 [TBL] [Abstract][Full Text] [Related]
12. Upregulated HOXC8 Expression Is Associated with Poor Prognosis and Oxaliplatin Resistance in Hepatocellular Carcinoma. Xu P; Zhang X; Ni W; Fan H; Xu J; Chen Y; Zhu J; Gu X; Yang L; Ni R; Chen B; Shi W Dig Dis Sci; 2015 Nov; 60(11):3351-63. PubMed ID: 26123838 [TBL] [Abstract][Full Text] [Related]
13. The role of lncRNAs in hepatocellular carcinoma: opportunities as novel targets for pharmacological intervention. Zou H; Shao CX; Zhou QY; Zhu GQ; Shi KQ; Braddock M; Huang DS; Zheng MH Expert Rev Gastroenterol Hepatol; 2016; 10(3):331-40. PubMed ID: 26558504 [TBL] [Abstract][Full Text] [Related]
14. The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma. Pollutri D; Patrizi C; Marinelli S; Giovannini C; Trombetta E; Giannone FA; Baldassarre M; Quarta S; Vandewynckel YP; Vandierendonck A; Van Vlierberghe H; Porretti L; Negrini M; Bolondi L; Gramantieri L; Fornari F Cell Death Dis; 2018 Jan; 9(1):4. PubMed ID: 29305580 [TBL] [Abstract][Full Text] [Related]
15. Dysregulation of non-coding RNAs mediates cisplatin resistance in hepatocellular carcinoma and therapeutic strategies. Xu XF; Yang XK; Song Y; Chen BJ; Yu X; Xu T; Chen ZL Pharmacol Res; 2022 Feb; 176():105906. PubMed ID: 34543740 [TBL] [Abstract][Full Text] [Related]
16. Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel? Gnoni A; Santini D; Scartozzi M; Russo A; Licchetta A; Palmieri V; Lupo L; Faloppi L; Palasciano G; Memeo V; Angarano G; Brunetti O; Guarini A; Pisconti S; Lorusso V; Silvestris N Expert Opin Ther Targets; 2015; 19(12):1623-35. PubMed ID: 26212068 [TBL] [Abstract][Full Text] [Related]
18. Bioinformatics analysis reveals potential candidate drugs for HCC. Huang XB; Li J; Zheng L; Zuo GH; Han KQ; Li HY; Liang P Pathol Oncol Res; 2013 Apr; 19(2):251-8. PubMed ID: 23341104 [TBL] [Abstract][Full Text] [Related]
19. Long Noncoding RNA (lncRNA) Small Nucleolar RNA Host Gene 16 (SNHG16) Predicts Poor Prognosis and Sorafenib Resistance in Hepatocellular Carcinoma. Guo Z; Zhang J; Fan L; Liu J; Yu H; Li X; Sun G Med Sci Monit; 2019 Mar; 25():2079-2086. PubMed ID: 30893293 [TBL] [Abstract][Full Text] [Related]
20. A selective c-Met and Trks inhibitor Indo5 suppresses hepatocellular carcinoma growth. Luo T; Zhang SG; Zhu LF; Zhang FX; Li W; Zhao K; Wen XX; Yu M; Zhan YQ; Chen H; Ge CH; Gao HY; Wang L; Yang XM; Li CY J Exp Clin Cancer Res; 2019 Mar; 38(1):130. PubMed ID: 30885237 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]